Table 1.

Clinical Characteristics of Patients With MPNs Who Developed AML/MDS and Matched Controls

Characteristic	Patient Cases		Controls
	No.	%	No.	%
Total	162	100	242	100
Sex
Female	67	41	101	42
Male	95	59	141	58
MPN subtype
PV	110	68	176	73
ET	26	16	39	16
PMF	15	9	23	9
MPN NOS	11	7	4	2
Age at MPN diagnosis, years
< 49	17	10	20	8
50-59	35	22	55	23
60-69	55	34	91	38
> 70	55	34	76	31
Median	64		65
Range	17-85		35-86
Type of transformation
AML	153	94	—
MDS	9	6	—
Calendar period of MPN diagnosis
1958-1969	32	20	44	18
1970-1979	23	14	39	16
1980-1989	41	25	58	24
1990-1999	51	31	81	33
2000-2005	15	9	20	8
Treatment
None	41	25	78	32
Alk only	12	7	29	12
P32 only	39	24	59	24
HU only	34	21	50	21
Alk + P32	19	12	13	5
Alk + HU	5	3	4	2
HU + P32	10	6	9	4
Alk + P32 + HU	2	1	0	0

Abbreviations: Alk, alkylating agent; AML, acute myeloid leukemia; ET, essential thrombocythemia; HU, hydroxyurea; MDS, myelodysplastic syndrome; MPN, chronic myeloproliferative neoplasm; NOS, not otherwise specified; P³², radioactive phosphorus; PMF, primary myelofibrosis; PV, polycythemia vera.